Merck’s phase 3 HYPERION study of Winrevair meets primary endpoint in recently diagnosed adults with pulmonary arterial hypertension: Rahway, New Jersey Tuesday, June 24, 2025, ...

Supercede Therapeutics, Inc., a startup biotech company focused on small molecule drug development, today announced preclinical efficacy data from its lead therapeutic program to treat obesity.

Topline results were announced from a phase 3 study evaluating sotatercept-csrk in recently diagnosed adults with pulmonary arterial hypertension (PAH).

Panelists discuss how riociguat targets the nitric oxide pathway and is approved for both Group 1 PAH and Group 4 chronic ...

Follistatin-344 (FS-344), a glycoprotein variant, has emerged as a focal point in scientific research due to its potential ...

本研究聚焦新生儿坏死性小肠结肠炎（NEC）的发病机制，揭示了Activin A通过激活ALK4-Smad2/3信号轴，加剧肠上皮细胞凋亡和屏障 ...

A Drug box of Ozempic containing Semaglutide for treatment of type 2 diabetes and long-term weight management on a table and ...

Cell signalling is the mechanism by which stimuli are transmitted via a signalling cascade to effector molecules that orchestrate the appropriate response. Types of cell signalling pathways ...

Sotatercept significantly reduced the risk of all-cause mortality, lung transplantation, or ≥24-hour hospitalization for ...